Hypertrophic Scar Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major hypertrophic scar markets reached a value of US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.3 Billion by 2034, exhibiting a growth rate (CAGR) of 6.51% during 2024-2034.
The hypertrophic scar market has been comprehensively analyzed in IMARC's new report titled "Hypertrophic Scar Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". A hypertrophic scar refers to a cutaneous condition in which raised, thickened, and wider scars occur around a healing wound due to an abnormal response to an injury or trauma. These scars are characterized by dermal tissue proliferation, prolonged over-deposition of extracellular matrix (ECM) proteins, particularly collagen, as well as persistent inflammation and fibrosis. The condition becomes evident within weeks of the injury and is limited to the area of damaged skin. Individuals suffering from this disorder may experience hard or thickened raised tissue, along with pink to red or purple skin color over the wound site, irritation, itching, tenderness, pain, mild discomfort, etc. In some cases, when a scar develops over the skin of a joint, it might impair the joint's normal movement. The diagnosis of this ailment is mainly based on the patient's medical history and clinical features. The healthcare provider may also perform a physical examination to evaluate the affected area. Additionally, a skin biopsy is required to confirm a diagnosis if the scar continues to change or worsen.
The increasing cases of injury or trauma to the skin, including surgical incisions, burns, cuts, abrasions, etc., are primarily driving the hypertrophic scar market. Furthermore, the rising prevalence of several associated risk factors, such as genetic predisposition, bacterial or fungal infections at the wound site, poor wound care, herpes zoster infection, chicken pox, etc., is also propelling the market growth. In addition to this, the escalating utilization of various medications, including corticosteroid and bleomycin injections, which can soften and flatten the scar and ease symptoms like itching and pain, is creating a positive outlook for the market. Moreover, the inflating usage of tension-releasing surgical techniques, such as Z-plasty and local flap methods, for patients with advanced disease conditions who have failed conservative treatments is also bolstering the market growth. Apart from this, the emerging popularity of laser therapies, since they are less painful and uncomfortable than other scar treatment options like surgical scar revision, is acting as another significant growth-inducing factor. Additionally, the widespread adoption of silicone sheets or ointments to lower scar appearance and improve skin texture in patients is expected to drive the hypertrophic scar market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the hypertrophic scar market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hypertrophic scar and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hypertrophic scar market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hypertrophic scar market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hypertrophic scar market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hypertrophic scar marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hypertrophic scar market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hypertrophic scar market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hypertrophic scar market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hypertrophic scar across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypertrophic scar by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypertrophic scar by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hypertrophic scar across the seven major markets?
What is the size of the hypertrophic scar patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hypertrophic scar?
What will be the growth rate of patients across the seven major markets?
Hypertrophic Scar: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hypertrophic scar drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hypertrophic scar market?
What are the key regulatory events related to the hypertrophic scar market?
What is the structure of clinical trial landscape by status related to the hypertrophic scar market?
What is the structure of clinical trial landscape by phase related to the hypertrophic scar market?
What is the structure of clinical trial landscape by route of administration related to the hypertrophic scar market?
The hypertrophic scar market has been comprehensively analyzed in IMARC's new report titled "Hypertrophic Scar Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". A hypertrophic scar refers to a cutaneous condition in which raised, thickened, and wider scars occur around a healing wound due to an abnormal response to an injury or trauma. These scars are characterized by dermal tissue proliferation, prolonged over-deposition of extracellular matrix (ECM) proteins, particularly collagen, as well as persistent inflammation and fibrosis. The condition becomes evident within weeks of the injury and is limited to the area of damaged skin. Individuals suffering from this disorder may experience hard or thickened raised tissue, along with pink to red or purple skin color over the wound site, irritation, itching, tenderness, pain, mild discomfort, etc. In some cases, when a scar develops over the skin of a joint, it might impair the joint's normal movement. The diagnosis of this ailment is mainly based on the patient's medical history and clinical features. The healthcare provider may also perform a physical examination to evaluate the affected area. Additionally, a skin biopsy is required to confirm a diagnosis if the scar continues to change or worsen.
The increasing cases of injury or trauma to the skin, including surgical incisions, burns, cuts, abrasions, etc., are primarily driving the hypertrophic scar market. Furthermore, the rising prevalence of several associated risk factors, such as genetic predisposition, bacterial or fungal infections at the wound site, poor wound care, herpes zoster infection, chicken pox, etc., is also propelling the market growth. In addition to this, the escalating utilization of various medications, including corticosteroid and bleomycin injections, which can soften and flatten the scar and ease symptoms like itching and pain, is creating a positive outlook for the market. Moreover, the inflating usage of tension-releasing surgical techniques, such as Z-plasty and local flap methods, for patients with advanced disease conditions who have failed conservative treatments is also bolstering the market growth. Apart from this, the emerging popularity of laser therapies, since they are less painful and uncomfortable than other scar treatment options like surgical scar revision, is acting as another significant growth-inducing factor. Additionally, the widespread adoption of silicone sheets or ointments to lower scar appearance and improve skin texture in patients is expected to drive the hypertrophic scar market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the hypertrophic scar market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hypertrophic scar and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hypertrophic scar market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hypertrophic scar market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hypertrophic scar market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hypertrophic scar marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hypertrophic scar market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hypertrophic scar market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hypertrophic scar market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hypertrophic scar across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypertrophic scar by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypertrophic scar by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hypertrophic scar across the seven major markets?
What is the size of the hypertrophic scar patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hypertrophic scar?
What will be the growth rate of patients across the seven major markets?
Hypertrophic Scar: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hypertrophic scar drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hypertrophic scar market?
What are the key regulatory events related to the hypertrophic scar market?
What is the structure of clinical trial landscape by status related to the hypertrophic scar market?
What is the structure of clinical trial landscape by phase related to the hypertrophic scar market?
What is the structure of clinical trial landscape by route of administration related to the hypertrophic scar market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HYPERTROPHIC SCAR - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HYPERTROPHIC SCAR - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HYPERTROPHIC SCAR - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 HYPERTROPHIC SCAR - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HYPERTROPHIC SCAR - UNMET NEEDS
10 HYPERTROPHIC SCAR - KEY ENDPOINTS OF TREATMENT
11 HYPERTROPHIC SCAR - MARKETED PRODUCTS
11.1 List of Hypertrophic Scar Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 HYPERTROPHIC SCAR - PIPELINE DRUGS
12.1 List of Hypertrophic Scar Pipeline Drugs Across the Top 7 Markets
12.1.1 STP705- Sirnaomics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 OLX10010 - OliX Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HYPERTROPHIC SCAR - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HYPERTROPHIC SCAR – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HYPERTROPHIC SCAR - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hypertrophic Scar - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hypertrophic Scar - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hypertrophic Scar - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hypertrophic Scar - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hypertrophic Scar - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hypertrophic Scar - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hypertrophic Scar - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hypertrophic Scar - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hypertrophic Scar - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hypertrophic Scar - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hypertrophic Scar - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hypertrophic Scar - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hypertrophic Scar - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hypertrophic Scar - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hypertrophic Scar - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hypertrophic Scar - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hypertrophic Scar - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hypertrophic Scar - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hypertrophic Scar - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hypertrophic Scar - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hypertrophic Scar - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hypertrophic Scar - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hypertrophic Scar - Access and Reimbursement Overview
16 HYPERTROPHIC SCAR - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HYPERTROPHIC SCAR MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HYPERTROPHIC SCAR MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HYPERTROPHIC SCAR - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HYPERTROPHIC SCAR - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HYPERTROPHIC SCAR - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 HYPERTROPHIC SCAR - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HYPERTROPHIC SCAR - UNMET NEEDS
10 HYPERTROPHIC SCAR - KEY ENDPOINTS OF TREATMENT
11 HYPERTROPHIC SCAR - MARKETED PRODUCTS
11.1 List of Hypertrophic Scar Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 HYPERTROPHIC SCAR - PIPELINE DRUGS
12.1 List of Hypertrophic Scar Pipeline Drugs Across the Top 7 Markets
12.1.1 STP705- Sirnaomics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 OLX10010 - OliX Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HYPERTROPHIC SCAR - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HYPERTROPHIC SCAR – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HYPERTROPHIC SCAR - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hypertrophic Scar - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hypertrophic Scar - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hypertrophic Scar - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hypertrophic Scar - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hypertrophic Scar - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hypertrophic Scar - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hypertrophic Scar - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hypertrophic Scar - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hypertrophic Scar - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hypertrophic Scar - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hypertrophic Scar - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hypertrophic Scar - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hypertrophic Scar - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hypertrophic Scar - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hypertrophic Scar - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hypertrophic Scar - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hypertrophic Scar - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hypertrophic Scar - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hypertrophic Scar - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hypertrophic Scar - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hypertrophic Scar - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hypertrophic Scar - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hypertrophic Scar - Access and Reimbursement Overview
16 HYPERTROPHIC SCAR - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HYPERTROPHIC SCAR MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HYPERTROPHIC SCAR MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
